DISCUSSION
CIC
CIC has been reported to affect some demographic groups more than others, such as female individuals and the older population more often than male or younger individuals (In patients with CIC subgrouped by age (younger than 65 years and aged 65 years or older), sex/gender (female and male individuals), race/ethnicity (White and non-White individuals), and BMI subcategorized into 3 groups (<25 kg/mLimitations of this analysis include those inherent to the nature of post hoc and exploratory analyses. Combining the 2 trials was justified because of parallel study designs, geographic participation, treatment dosing and duration, and patient baseline characteristics. Despite the general increase in subgroup sample size by pooling of data, some subgroups were limited in size, which may have precluded the ability to detect differences between plecanatide and placebo. In addition, we analyzed a limited number of demographic variables, and future studies should evaluate additional factors as well.In conclusion, although CIC is associated with differences in the prevalence of demographic and clinical characteristics, such as age, sex/gender, race/ethnicity, and BMI, these pooled analyses showed that the plecanatide clinical efficacy profile was superior to placebo, and the safety profile of plecanatide was comparable across all subgroups.